We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
(+7.8%)
Cap. Flow
-$725M
Cap. Flow
% of AUM
-39.12%
Top 10 Holdings %
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIOA
BioAmber Inc.
BIOA
|
+$5.55M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$5.2M |
| 3 |
OTIC
Otonomy, Inc.
OTIC
|
+$3.92M |
| 4 |
BLRX
BioLineRX
BLRX
|
+$3.37M |
| 5 |
SELLAS Life Sciences
SLS
|
+$2.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$62.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$59.7M |
| 3 |
Amgen
AMGN
|
+$35.8M |
| 4 |
Eli Lilly
LLY
|
+$15.7M |
| 5 |
Biogen
BIIB
|
+$5.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 6.29% |
| 2 | Materials | 0.25% |
| 3 | Financials | 0.16% |
| 4 | Consumer Staples | 0.04% |
| 5 | Consumer Discretionary | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Merck
MRK
$322B
| $270M | 14.54% |
44,459
+31,204
| +235% | +$1.89M |
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $144M | 7.76% |
6,100
+100
| +2% | +$23.2K |
|
|
3
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $141M | 7.63% |
+5,999
| New | +$1.39M |
|
4
CALL
AbbVie
ABBV
$465B
| $109M | 5.86% |
16,669
+14,465
| +656% | +$909K |
|
5
PUT
Bristol-Myers Squibb
BMY
$129B
| $100M | 5.42% |
18,473
+9,995
| +118% | +$548K |
|
|
6
CALL
Bristol-Myers Squibb
BMY
$129B
| $76.2M | 4.11% |
14,019
+8,600
| +159% | +$472K |
|
7
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
| $70.3M | 3.79% |
+9,448
| New | +$689K |
|
8
CALL
iShares S&P 100 ETF
OEF
$19.5B
| $68.7M | 3.71% |
+5,000
| New | +$516K |
|
9
CALL
Gilead Sciences
GILD
$165B
| $56.3M | 3.04% |
8,286
+3,969
| +92% | +$279K |
|
|
10
PUT
Amgen
AMGN
$209B
| $50.1M | 2.7% |
3,055
-639
| -17% | -$106K |
|
11
CALL
AstraZeneca
AZN
$269B
| $45.7M | 2.46% |
+7,337
| New | +$427K |
|
|
12
PUT
iShares S&P 100 ETF
OEF
$19.5B
| $42.6M | 2.3% |
3,100
-4,319
| -58% | -$446K |
|
|
ALXN
13
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $34.2M | 1.84% |
2,817
+1,231
| +78% | +$159K |
|
14
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.94B
| $30.4M | 1.64% |
4,388
-235
| -5% | -$15.5K |
|
15
CALL
Cigna
CI
$78.4B
| $23.1M | 1.25% |
+1,580
| New | +$233K |
|
|
16
PUT
Merck
MRK
$322B
| $21.1M | 1.14% |
+3,487
| New | +$212K |
|
|
CLVS
17
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $20.7M | 1.12% |
3,252
-126
| -4% | -$7.66K |
|
18
CALL
United Therapeutics
UTHR
$26.1B
| $19.1M | 1.03% |
1,410
+1,147
| +436% | +$174K |
|
19
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
| $17.3M | 0.93% |
+1,969
| New | +$175K |
|
|
BLUE
20
CALL
DELISTED
bluebird bio
BLUE
| $17.3M | 0.93% |
147
+101
| +220% | +$103K |
|
21
CALL
Vertex Pharmaceuticals
VRTX
$123B
| $15M | 0.81% |
1,376
+306
| +29% | +$26.9K |
|
|
ACOR
22
PUT
DELISTED
Acorda Therapeutics
ACOR
| $14.7M | 0.79% |
58
+7
| +14% | +$20.1K |
|
|
PTLA
23
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $14M | 0.75% |
3,560
+1,757
| +97% | +$56K |
|
|
24
PUT
AstraZeneca
AZN
$269B
| $13.2M | 0.71% |
+2,119
| New | +$123K |
|
|
25
CALL
Amgen
AMGN
$209B
| $13.1M | 0.71% |
798
+497
| +165% | +$82.6K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
AB
Sabby Management's Q1 2017 Portfolio in Review
As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.
Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.
- Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
- Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
- Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
- Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
- Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
- Sabby Management opened 79 new positions and closed 116 in Q1 2017.
- Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.
Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.